Glycoprotein IIb/IIIa inhibitors

WikiDoc Resources for Glycoprotein IIb/IIIa inhibitors
Articles
Most recent articles on Glycoprotein IIb/IIIa inhibitors Most cited articles on Glycoprotein IIb/IIIa inhibitors Review articles on Glycoprotein IIb/IIIa inhibitors Articles on Glycoprotein IIb/IIIa inhibitors in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Glycoprotein IIb/IIIa inhibitors Images of Glycoprotein IIb/IIIa inhibitors Photos of Glycoprotein IIb/IIIa inhibitors Podcasts & MP3s on Glycoprotein IIb/IIIa inhibitors Videos on Glycoprotein IIb/IIIa inhibitors
Evidence Based Medicine
Cochrane Collaboration on Glycoprotein IIb/IIIa inhibitors Bandolier on Glycoprotein IIb/IIIa inhibitors TRIP on Glycoprotein IIb/IIIa inhibitors
Clinical Trials
Ongoing Trials on Glycoprotein IIb/IIIa inhibitors at Clinical Trials.gov Trial results on Glycoprotein IIb/IIIa inhibitors Clinical Trials on Glycoprotein IIb/IIIa inhibitors at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Glycoprotein IIb/IIIa inhibitors NICE Guidance on Glycoprotein IIb/IIIa inhibitors NHS PRODIGY Guidance FDA on Glycoprotein IIb/IIIa inhibitors CDC on Glycoprotein IIb/IIIa inhibitors
Books
Books on Glycoprotein IIb/IIIa inhibitors
News
Glycoprotein IIb/IIIa inhibitors in the news Be alerted to news on Glycoprotein IIb/IIIa inhibitors News trends on Glycoprotein IIb/IIIa inhibitors
Commentary
Blogs on Glycoprotein IIb/IIIa inhibitors
Definitions
Definitions of Glycoprotein IIb/IIIa inhibitors
Patient Resources / Community
Patient resources on Glycoprotein IIb/IIIa inhibitors Discussion groups on Glycoprotein IIb/IIIa inhibitors Patient Handouts on Glycoprotein IIb/IIIa inhibitors Directions to Hospitals Treating Glycoprotein IIb/IIIa inhibitors Risk calculators and risk factors for Glycoprotein IIb/IIIa inhibitors
Healthcare Provider Resources
Symptoms of Glycoprotein IIb/IIIa inhibitors Causes & Risk Factors for Glycoprotein IIb/IIIa inhibitors Diagnostic studies for Glycoprotein IIb/IIIa inhibitors Treatment of Glycoprotein IIb/IIIa inhibitors
Continuing Medical Education (CME)
CME Programs on Glycoprotein IIb/IIIa inhibitors
International
Glycoprotein IIb/IIIa inhibitors en Espanol Glycoprotein IIb/IIIa inhibitors en Francais
Business
Glycoprotein IIb/IIIa inhibitors in the Marketplace Patents on Glycoprotein IIb/IIIa inhibitors
Experimental / Informatics
List of terms related to Glycoprotein IIb/IIIa inhibitors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Glycoprotein IIb/IIIa inhibitors, also GpIIb/IIIa inhibitors, are a class of antiplatelet agents.

Several GpIIb/IIIa inhibitors exist:

• Abciximab (ReoPro^®)
• Eptifibatide (Integrilin^®)
• Tirofiban (Aggrastat^®)

Indications

Glycoprotein IIb/IIIa inhibitors are frequently used during percutaneous coronary interventions (angioplasty with or without intracoronary stent placement).

They work by preventing platelet aggregation and thrombus formation. They do so by inhibition of the GpIIb/IIIa receptor on the surface of the platelets. By blocking the GPIIbIIIa receptor, they block the ability of platelets to cross link via fibrinogen.

The agents in this class are administered intravenously. Oral forms of these agents were associated with increased mortality, possibly due to underdosing of the agents.

History

Their development arose from the understanding of Glanzmann's thrombasthenia, a condition in which the GpIIb/IIIa is lacking.

Additional Resources

• The MD TV: Comments on Hot Topics, State of the Art Presentations in Cardiovascular Medicine, Expert Reviews on Cardiovascular Research
• Clinical Trial Results: An up to dated resource of Glycoprotein IIb/IIIa inhibitors related clinical trials

Template:WikiDoc Sources